On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the pathophysiology as a multi-stage cascade beginning with calcium dysregulation in pancreatic acinar cells. This leads to the premature conversion of trypsinogen to active trypsin, causing cellular autodigestion and the release of damage-associated molecular patterns (DAMPs) that trigger (SIRS).
- •Distinguish between the two clinical phases of the disease: the Early Phase (first week), dominated by the host's systemic inflammatory response and potential early organ failure, and the Late Phase (beyond one week), characterized by local complications such as peripancreatic fluid collections and persistent systemic inflammation.
- •Classify severity using the Revised Atlanta Classification (RAC), which categorizes AP into Mild (no organ failure or complications), Moderately Severe (transient organ failure < 48 hours or local/systemic complications), and Severe (persistent organ failure > 48 hours).
- •Identify the primary etiologies, noting that and biliary sludge account for 40–60% of cases, while alcohol consumption accounts for 20–30%. Metabolic triggers, specifically , become a critical risk when serum levels exceed 1,000 mg/dL (11.3 mmol/L).
- •Recognize the "Enigmatic Triad" of (DKA), hypertriglyceridemia, and acute pancreatitis, where each condition can potentially precipitate the others, complicating the initial diagnostic and metabolic stabilization efforts.
- •Note morphological variants including Interstitial Edematous Pancreatitis (IEP), characterized by diffuse enlargement without necrosis, and Necrotizing Pancreatitis, which involves tissue death of the parenchyma or peripancreatic tissues and carries a higher risk of infection.
Evaluation
- •Suspect acute pancreatitis in any patient presenting with sudden-onset, constant, and severe epigastric pain that often radiates to the back and is described as "boring" or "stabbing." Nausea and vomiting are nearly universal and typically do not relieve the pain.
- •Ask about specific risk factors including alcohol intake, history of symptomatic , recent procedures, and medications such as , , or (gliptins).
- •Examine the patient for signs of SIRS, specifically monitoring for tachycardia (HR > 90 bpm), tachypnea, and fever. Persistent tachycardia over the first 7 days is a strong predictor of mortality and infectious pancreatic necrosis.
- •Perform a thorough abdominal exam to identify guarding or rebound tenderness, which may suggest necrotic collections or an . Look for rare hemorrhagic signs like Cullen’s sign (periumbilical ecchymosis) or Grey Turner’s sign (flank ecchymosis).
- •Order a serum lipase level immediately; a value ≥ 3 times the upper limit of normal is highly suggestive of AP. Note that amylase is less specific and may return to normal more quickly than lipase.
- •Obtain a complete metabolic panel and lipid profile to screen for and assess renal function (creatinine) and liver enzymes (ALT > 150 U/L suggests a biliary etiology).
- •Calculate the Neutrophil-to-Lymphocyte Ratio (NLR) at admission and at 48 hours; a rising or persistently elevated NLR is a low-cost marker for predicting persistent organ failure.
- •Monitor for "Red Flags" indicating the need for ICU escalation, including hypotension unresponsive to initial fluids, altered mental status, or respiratory distress (FVC < 15 mL/kg or rising oxygen requirements).
- •Utilize the Modified Marshall Scoring System to objectively define organ failure across the respiratory (PaO2/FiO2 ratio), renal (serum creatinine), and cardiovascular (systolic blood pressure) systems.
- •Order a contrast-enhanced computed tomography (CECT) scan only if the diagnosis is uncertain or if the patient fails to improve after 48–72 hours, as early imaging may underrepresent the extent of pancreatic necrosis.
- •Screen for on the extensor surfaces of the extremities if hypertriglyceridemic pancreatitis is suspected, and assess for which correlates with worse clinical outcomes.
Management
- •Administer aggressive fluid resuscitation with isotonic crystalloids (Lactated Ringer's is often preferred) at 250–500 mL/h initially, unless cardiovascular or renal contraindications exist. Frequent reassessment of fluid status every 6–12 hours is mandatory to avoid fluid overload.
- •Initiate early enteral nutrition (oral or tube feeding) within 24 hours if tolerated, as it maintains the intestinal barrier and reduces the risk of bacterial translocation and infected necrosis compared to parenteral nutrition.
- •Manage pain aggressively using intravenous opioids (e.g., hydromorphone or fentanyl) or multimodal analgesia; avoid relying solely on NSAIDs in the acute phase due to renal risks.
- •Avoid prophylactic antibiotics in patients with sterile necrosis; antibiotics should be reserved for suspected or confirmed infected necrosis (e.g., new fever, rising WBC, or gas on CT).
- •Administer carbapenems (e.g., Meropenem 1g IV every 8 hours) or quinolones with metronidazole if infected necrosis is confirmed, as these agents have superior pancreatic tissue penetration.
- •Implement the "Step-Up" approach for infected pancreatic necrosis: start with percutaneous or endoscopic ultrasound-guided transluminal drainage (EUS-TD) before considering minimally invasive necrosectomy.
- •Utilize lumen-apposing metal stents (LAMS) for the drainage of walled-off necrosis (WON) to improve drainage efficiency and facilitate early nutritional recovery.
- •Treat severe (TG > 1,000 mg/dL) with an insulin infusion (0.1 units/kg/hour) or plasmapheresis to rapidly lower lipid levels and prevent further acinar injury.
- •Perform a during the same admission for all patients with mild biliary pancreatitis to prevent recurrent attacks; for severe cases, delay surgery until inflammatory collections have stabilized.
- •Monitor Procalcitonin (PCT) levels; a value > 1.0 ng/mL is highly suggestive of pancreatic necrosis and may guide the decision for invasive sampling.
- •Initiate Pancreatic Enzyme Replacement Therapy (PERT) (e.g., Creon 25,000–50,000 units per meal) in patients showing signs of malabsorption or those recovering from necrotizing pancreatitis to manage exocrine insufficiency.
- •Refer patients with persistent organ failure, extensive necrosis, or complex local complications to a tertiary specialized center early (within 24–48 hours) to reduce the risk of progression to SAP.
- •Monitor for pancreatic encephalopathy, characterized by confusion or neurological deficits, which may result from the systemic release of pancreatic enzymes like phospholipase A2.
- •Discharge patients once pain is controlled with oral medications, they can tolerate an oral diet, and systemic inflammatory markers are trending downward. Ensure a follow-up plan for repeat imaging if local collections were present.
Board Review — High Yield
- •Cullen's sign — Periumbilical ecchymosis indicating retroperitoneal hemorrhage/hemorrhagic pancreatitis.
- •Grey Turner's sign — Flank ecchymosis associated with severe necrotizing pancreatitis.
- •Sentinel Loop — A localized ileus of a jejunal loop seen on abdominal X-ray near the inflamed pancreas.
- •Revised Atlanta Classification — Defines severity based on organ failure duration: transient (<48h) vs persistent (>48h).
- •Hypertriglyceridemia — AP risk increases significantly when serum triglycerides exceed 1,000 mg/dL.
- •Step-up approach — The strategy of using percutaneous/endoscopic drainage before surgical necrosectomy for infected necrosis.
- •Pancreatic Encephalopathy — Neurological symptoms caused by circulating pancreatic enzymes and cytokine-mediated neuroinflammation.
- •Iatrogenic triggers — Post-ERCP pancreatitis is a common complication; risk is higher in patients with intrapancreatic fat deposition.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Acute pancreatitis is an acute inflammatory pancreatic disorder with a spectrum from self-limited disease to organ failure and death.[106]
- ▸The principal severity categories are mild, moderately severe, and severe AP under the Revised Atlanta Classification.[108][112][114][115]
- ▸Severe AP is defined chiefly by persistent organ failure lasting **more than 48 hours**.[108][114]
- ▸HTG-AP is an etiologic subtype, whereas HTG-SAP combines hypertriglyceridemic etiology with severe Revised Atlanta classification.[113][117]
- ▸PPAP and other postoperative forms should not be treated as interchangeable with spontaneous AP because procedure-specific definitions apply.[20][187]
- ▸Risk scores and biomarkers support prognostication but do not replace the Revised Atlanta diagnostic and severity framework.[7][9][107][112][115]
Definition
Acute pancreatitis (AP) is an acute inflammatory pancreatic disorder with a clinically heterogeneous course, ranging from a self-limited illness to systemic complications, persistent organ failure, and death.[106] Although many episodes resolve without major sequelae, up to approximately one-third of patients may develop complications associated with increased morbidity and mortality.[106] Contemporary diagnosis and severity assessment should use an integrated clinical, biochemical, and imaging approach within the framework of the Revised Atlanta Classification.[106][108]
In clinical practice, AP is diagnosed when the overall presentation is compatible with acute pancreatic inflammation and the accepted diagnostic framework is fulfilled; the Revised Atlanta system is then used to classify the episode by severity and complications.[106][108] Non-contrast CT, contrast-enhanced CT, and emerging automated CT methods may support diagnosis or stratification when clinical assessment is uncertain, but imaging-based technologies should be interpreted in the context of the clinical presentation.[108][114]
Synonyms and related terminology
The standard abbreviation is AP, meaning acute pancreatitis.[106] The following terms are related but should not be treated as interchangeable synonyms:
- Acute pancreatitis (AP): the general diagnostic term for an acute episode.[106]
- Severe acute pancreatitis (SAP): AP meeting the Revised Atlanta definition of severe disease, principally based on persistent organ failure.[108][114]
- Hypertriglyceridemic acute pancreatitis (HTG-AP): AP associated with hypertriglyceridemia; this is an etiologic subtype rather than a separate severity category.[113][117]
- Hypertriglyceridemic severe acute pancreatitis (HTG-SAP): HTG-AP classified as severe according to the Revised Atlanta system.[117]
- Post-pancreatectomy acute pancreatitis (PPAP): postoperative AP occurring after pancreatic resection; it has procedure-specific diagnostic definitions and should be distinguished from spontaneous AP.[20]D
- Postoperative acute pancreatitis after pancreatoduodenectomy: a related postoperative entity for which several partly overlapping definitions have been evaluated; the Atlanta-Helsinki grading proposal was developed specifically in this surgical context.[187]
Terminology such as “complicated AP,” “necrotizing AP,” or “organ-failure AP” describes clinically important manifestations or phenotypes rather than universal synonyms for AP.[106][108] Similarly, inflammatory biomarkers, body-composition measures, and prediction scores may correlate with severity but do not redefine AP itself.[7][8][9][10][112][115]
Classification by severity
The Revised Atlanta Classification separates AP into mild, moderately severe, and severe disease.[108][112][114][115]
- Mild AP: AP without organ failure or major local or systemic complications.[108][112]
- Moderately severe AP: AP with transient organ failure and/or local or systemic complications without persistent organ failure.[108][112]
- Severe AP: AP with persistent organ failure for more than 48 hours; this threshold is the principal reference standard for severe disease and may delay definitive classification during the first 48 hours.[108][114]
Severity is therefore dynamic. A patient initially classified as not severe may progress to severe AP, while early clinical indicators can identify increased risk before the 48-hour criterion is fully established.[114][115] BISAP and APACHE II are examples of early risk-stratification tools evaluated against Revised Atlanta severity and mortality outcomes, but they are prediction instruments rather than replacements for the classification itself.[115] Other investigated markers—including platelet-to-lymphocyte ratio, neutrophil percentage-to-albumin ratio, immune biomarkers, and oxidative-stress markers—may provide prognostic information, but their definitions and performance vary across studies and should not be used as independent disease classifications.[7][9][107][112]
Classification by etiology and clinical context
AP may be categorized according to its presumed cause, including hypertriglyceridemia, although the supplied evidence does not establish a single universal etiologic taxonomy.[113][117] Substance exposure is also clinically relevant: observational evidence has specifically examined combined use of tobacco, alcohol, cannabis, and illicit substances in relation to pancreatitis risk.[2] Obesity, sarcopenia, visceral adiposity, and reduced skeletal-muscle measures are associated in contemporary studies with disease severity or adverse outcomes, but these characteristics are risk modifiers rather than diagnostic categories.[8][10][186]
The classification should also record local and systemic complications when present. Imaging-based studies and clinical guidelines continue to use the Revised Atlanta categories of mild, moderately severe, and severe AP as the principal common language for diagnosis, research, and outcome reporting.[106][108][112][114] Postoperative pancreatic inflammation requires additional procedural context because definitions may depend on sustained postoperative hyperamylasemia, symptoms, imaging findings, and the type of pancreatic operation.[20]D[187]
| Term | Meaning | Classification role |
|---|---|---|
| AP | Acute pancreatitis | General diagnostic term [106] |
| Mild AP | No organ failure or major complications | Lowest Revised Atlanta severity category [108][112] |
| Moderately severe AP | Transient organ failure and/or complications without persistent organ failure | Intermediate category [108][112] |
| Severe AP (SAP) | Persistent organ failure for >48 h | Highest Revised Atlanta severity category [108][114] |
| HTG-AP | Hypertriglyceridemia-associated AP | Etiologic subtype [113][117] |
| PPAP | Post-pancreatectomy acute pancreatitis | Procedure-associated entity requiring postoperative criteria [20]D[187] |
Etiology and Triggering Factors
- ▸The cited evidence supports gallstone disease, severe hypertriglyceridemia, and ERCP-related injury as principal etiologic contexts for AP [120,122,131].
- ▸FCS is a genetic cause of severe hypertriglyceridemia and recurrent AP due to functional lipoprotein-lipase deficiency [123].
- ▸The FCS screening study defined severe hypertriglyceridemia as **>885 mg/dL** [128].
- ▸Current smoking was evaluated as a predictor of recurrence after first-episode HTG-AP [126].
- ▸PEP diagnostic criteria in the cited pediatric study included abdominal pain plus pancreatic enzymes **>3× the upper limit of normal** [137].
Overview
The references supplied for this update support three principal etiologic or triggering contexts for acute pancreatitis (AP): gallstone disease, severe hypertriglyceridemia, and procedure-related pancreatic injury after endoscopic retrograde cholangiopancreatography (ERCP). Additional evidence concerns genetic susceptibility, smoking-related recurrence, body composition, and pediatric endoscopic intervention. The cited studies do not provide a comprehensive frequency ranking of all AP causes; therefore, etiologies not addressed in these references are not expanded here.
Gallstone-related acute pancreatitis
Gallstone disease is a major clinical context for AP in the cited literature. Studies evaluated adults with first episodes of gallstone-related AP and assessed subsequent management with cholecystectomy, ERCP alone, or no intervention [131]. The same study described same-admission cholecystectomy as guideline-recommended for mild gallstone-related AP, although surgery is frequently deferred [131]. Evidence also addressed choledocholithiasis, including ERCP for ductal stone clearance followed by laparoscopic cholecystectomy [133][134].
Gallstone-related triggering may recur when the underlying biliary source is not definitively managed. In a nationwide Swedish cohort, cholecystectomy, ERCP alone, and no intervention were compared for recurrent AP and other gallstone-related complications, with death treated as a competing event [131]. A separate updated systematic review compared cholecystectomy with conservative management for symptomatic uncomplicated gallstones and mild acute cholecystitis, particularly in patients at high surgical risk [121]. Prophylactic biliary stenting after complete stone extraction while awaiting cholecystectomy has also been evaluated, although the cited abstract focuses on recurrent choledocholithiasis and does not establish stenting as a pancreatitis-prevention strategy [124].
Hypertriglyceridemia-associated acute pancreatitis
Severe hypertriglyceridemia is a prominent metabolic trigger in the cited evidence. Hypertriglyceridemia-induced AP is characterized by markedly elevated triglycerides and may cause significant clinical complications [120]. The 2026 evidence base includes systematic reviews of triglyceride-lowering strategies—insulin, therapeutic plasma exchange, heparin, hemofiltration, and conservative treatment—reflecting the clinical importance of rapidly reducing triglyceride concentrations after presentation [120]. A separate meta-analysis evaluated apolipoprotein C-III (apoC3)-targeting antisense oligonucleotides and small-interfering RNA therapies for their effects on triglycerides, apoC3 concentrations, and AP incidence [119].
Familial chylomicronemia syndrome (FCS) is a monogenic form of severe hypertriglyceridemia associated with recurrent AP. It results from functional lipoprotein-lipase deficiency, which makes conventional triglyceride-lowering therapies ineffective [123]. Olezarsen and volanesorsen are targeted apoC-III inhibitors evaluated in FCS [123]. In a hospital-based screening study, severe hypertriglyceridemia was defined as triglycerides >885 mg/dL, and the FCS Clinical Score was used to distinguish probable FCS from multifactorial chylomicronemia syndrome [128]. This threshold should be interpreted as the study’s screening definition rather than a universal diagnostic cutoff [128].
Recurrence is an important consequence of persistent hypertriglyceridemic risk. A multicenter cohort specifically examined current smoking at the index hospitalization as a predictor of recurrence after a first episode of hypertriglyceridemia-induced AP [126]. Another retrospective cohort developed a model for 3-year recurrence using admission clinical and laboratory variables and CT-derived skeletal muscle density [135]. Prospective multicenter research has also focused on early prediction of severe HTG-AP, reflecting the reported tendency of HTG-AP to develop severe disease [136].
Procedure-related triggers: post-ERCP pancreatitis
ERCP is a recognized procedural trigger for AP in the supplied literature. Post-ERCP pancreatitis (PEP) was the primary outcome in a network meta-analysis of 41 trials involving 15,627 patients that compared rectal nonsteroidal anti-inflammatory drugs, aggressive lactated Ringer’s hydration, somatostatin, and combinations [122]. The study assessed both PEP and post-ERCP hyperamylasemia [122]. In pediatric patients with chronic pancreatitis undergoing endoscopic retrograde pancreatic duct drainage, PEP was defined by new or worsened abdominal pain together with amylase or lipase >3× the upper limit of normal, using ESGE 2020 criteria [137].
Patient and procedural characteristics may modify post-ERCP risk. A multicenter retrospective study evaluated visceral adipose tissue and other body-composition parameters as predictors of severe PEP [129]. In children with chronic pancreatitis, a single-center study investigated risk factors for PEP and whether standard versus longer pancreatic-stent exchange intervals affected pancreatitis occurrence [137]. The supplied abstracts do not report the individual independent risk factors or comparative effect estimates, so these findings should not be used to assign causality to a specific body-composition measure or stent interval.
Practical etiologic assessment
For a patient with AP, the references support focused assessment for biliary disease or ductal stones, severe hypertriglyceridemia, inherited chylomicronemia when the phenotype is severe or recurrent, and recent ERCP or pancreatic-duct instrumentation [120][123][128][131][137]. Smoking is supported as a potentially important modifiable predictor of recurrence specifically after HTG-AP, rather than as a proven proximate cause of the index episode in the cited cohort [126].
| Context | Evidence supported by the references | Clinical implication |
|---|---|---|
| Gallstone disease/choledocholithiasis | Cohorts and reviews evaluated gallstone-related AP, ductal stones, ERCP clearance, and cholecystectomy [121][131][133][134] | Investigate biliary disease and address the underlying gallstone source when appropriate [131] |
| Severe hypertriglyceridemia | HTG-AP was evaluated in systematic reviews and prediction cohorts [119][120][130][135][136] | Measure triglycerides and consider genetic chylomicronemia in severe or recurrent disease [120][128] |
| Familial chylomicronemia syndrome | Functional lipoprotein-lipase deficiency causes severe HTG and recurrent AP [123] | Conventional lipid-lowering therapy may be ineffective; targeted apoC-III inhibition has been studied [123] |
| ERCP/pancreatic instrumentation | PEP was assessed after ERCP and pancreatic-duct drainage [122][137] | Recent endoscopic intervention should be considered during etiologic assessment [122][137] |
| Modifiers of recurrence/severity | Smoking was studied for HTG-AP recurrence; visceral adipose tissue for severe PEP [126][129] | These findings indicate risk modification or stratification, not necessarily direct causation [126][129] |
Pathophysiology
- ▸AP involves interacting local pancreatic inflammation, systemic cytokine activation, intestinal barrier dysfunction, metabolic stress, and organ injury rather than a single mechanism. [140][193]
- ▸IL-1β, IL-6, and TNF-α contribute to inflammatory amplification, while IL-10 provides counter-regulation. [193]
- ▸Gut barrier injury may involve tight-junction disruption and NLRP3-inflammasome-associated pyroptosis. [147]
- ▸Acute liver injury occurred in 37.7% of patients in one retrospective AP cohort and was associated with higher NLR. [127]
- ▸Hypertriglyceridemic AP links lipidomic abnormalities, inflammation, and insulin-resistance-related metabolic stress with early severe progression. [189][149]
- ▸Admission fever, inflammatory indices, creatinine-linked indices, sarcopenia, and nutritional status are severity-associated markers or modifiers, not proven single-cause mechanisms. [141][112][144][148][150]
Acute pancreatitis (AP) is a dynamic inflammatory syndrome in which local pancreatic injury can be amplified into systemic inflammation, intestinal barrier dysfunction, and persistent organ failure. Contemporary evidence supports a model involving interacting immune, metabolic, vascular, nutritional, and microbiome-related pathways rather than a single causal mechanism. [140][193]
Local pancreatic inflammation and systemic immune activation
The inflammatory response begins with pancreatic injury and is characterized by rapid activation of innate immune pathways and release of cytokines. Circulating studies in AP demonstrate increases in IL-1α, IL-1β, IL-6, IL-10, IL-2Rα, interferon-γ, macrophage migration inhibitory factor, and other immune mediators compared with healthy controls. [193] Pro-inflammatory cytokines such as IL-1β, IL-6, and tumor necrosis factor-α may intensify inflammatory-cell recruitment and contribute to systemic complications, whereas IL-10 represents an opposing regulatory response. [193] The coexistence of pro- and anti-inflammatory signals helps explain why patients with apparently similar pancreatic injury may follow markedly different clinical courses. [193]
In severe AP, systemic inflammatory response syndrome (SIRS) may progress to multiorgan dysfunction. [188] The clinical expression of this systemic response includes inflammatory-cell abnormalities and early organ injury; in one retrospective cohort, acute liver injury occurred in 37.7% of patients with AP. [127] A higher neutrophil-to-lymphocyte ratio was associated with acute liver injury after adjustment for covariates, supporting the relationship between dysregulated systemic inflammation and extra-pancreatic organ damage, although the observational design does not establish causality. [127]
Gut barrier dysfunction and microbiota
The intestine is both a target and a potential amplifier of AP-related inflammation. Research synthesis identifies gut dysbiosis, intestinal barrier dysfunction, pancreatic inflammation, and disease progression as closely connected areas of investigation. [140] Experimental evidence indicates that AP-associated barrier injury involves epithelial tight-junction disruption and NLRP3-inflammasome-associated pyroptosis. [147] In a murine cerulein/lipopolysaccharide model and in lipopolysaccharide-stimulated intestinal epithelial cells, healthy-donor small extracellular-vesicle preparations improved tissue injury and restored tight-junction-related barrier integrity through a proposed miR-579-3p/ANXA3 pathway that inhibited NLRP3 inflammasome pyroptosis. [147] These findings support a mechanistic link between intestinal epithelial injury and systemic inflammatory propagation, but the intervention remains experimental and cannot be assumed to represent established human pathophysiology. [147]
Metabolic and lipid-mediated injury
Hypertriglyceridemic pancreatitis is associated with a higher risk of early severe progression, systemic complications, and mortality than many other etiologic categories. [189] Its pathobiology is linked to lipid-related metabolic stress and insulin resistance; the C-reactive-protein–triglyceride–glucose index was specifically investigated as a composite marker of inflammation and insulin resistance in hyperlipidemic AP. [149] Lipidomic modelling in a retrospective cohort of 288 patients was designed to identify signatures associated with progression from mild AP to moderately severe or severe AP, supporting the concept that disordered lipid metabolism may influence early severity. [189] These studies primarily identify associations and predictive signatures rather than proving that a specific lipid species directly causes pancreatic or systemic injury. [189][149]
Alcohol-related pancreatic injury may be intensified by concurrent hepatic inflammation. In a national retrospective cohort, alcohol-induced AP with concomitant alcohol-related hepatitis was evaluated for mortality, sepsis, acute kidney injury, respiratory failure, pulmonary edema, hepatic encephalopathy, and other complications, reflecting the potential for combined pancreatic and hepatic injury to increase systemic inflammatory and organ dysfunction burden. [194] The available evidence describes clinical association and outcome burden rather than a fully resolved molecular mechanism. [194]
Organ dysfunction, fever, and inflammatory severity markers
Persistent or escalating systemic inflammation is reflected clinically by organ dysfunction and laboratory indices that combine immune activation with impaired physiologic reserve. Admission neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index have been evaluated against Revised Atlanta severity categories. [112] The neutrophil-creatinine index combines neutrophil count with serum creatinine to represent inflammation alongside early renal dysfunction and was compared with BISAP, APACHE II, Ranson, and HAPS scores for severe AP prediction. [144] These indices are severity markers, not necessarily independent mechanistic drivers. [112][144]
Admission fever is associated with worse outcomes: a systematic review and meta-analysis evaluated febrile versus afebrile adults with AP for mortality and severity markers and reported that fever on admission was associated with increased disease severity and mortality. [141] This association may reflect a greater inflammatory or infectious burden, but fever alone does not establish infection or define the cause of pancreatic inflammation. [141]
Nutritional, muscular, and reserve-related modifiers
Nutritional status and physiologic reserve influence the host response to AP. A multicenter cohort examined sarcopenia using the psoas muscle index measured on admission CT and evaluated progression to moderately severe or severe AP. [148] A separate cohort assessed metabolic markers, inflammatory biomarkers, gut-barrier markers, dietary patterns, and early versus delayed enteral nutrition; early enteral nutrition was defined as initiation within 48 hours. [150] These studies support the concept that catabolic stress, impaired nutritional reserve, inflammation, and intestinal dysfunction interact during AP, although retrospective associations cannot determine whether malnutrition is a cause, consequence, or modifier of severity. [148][150]
Therapeutic implications of the inflammatory model
Because severe AP involves circulating inflammatory mediators and multiorgan dysfunction, extracorporeal removal has been investigated as an adjunct to medical therapy. In a retrospective cohort of 184 patients with severe AP, hemoperfusion followed by sequential hemodiafiltration was administered within 72 hours in the intervention group; propensity-score matching produced cohorts of 41 patients per group. [188] Inflammatory markers improved in both the hemoperfusion–hemodiafiltration and standard-treatment groups, indicating that extracorporeal therapy remains an adjunctive strategy rather than proof that one circulating mediator is solely responsible for disease progression. [188] No targeted pharmacological intervention is established by the cited evidence to interrupt the complete pathophysiologic cascade of severe AP. [188]
| Domain | Evidence-supported features | References |
|---|---|---|
| Immune activation | Increased pro-inflammatory and regulatory cytokines; SIRS may progress to multiorgan dysfunction | [188][193] |
| Intestinal axis | Dysbiosis, epithelial barrier dysfunction, tight-junction injury, and NLRP3-related pyroptosis | [140][147] |
| Metabolic injury | Hypertriglyceridemia, lipidomic abnormalities, inflammation, and insulin-resistance-related signals | [149][189] |
| Organ dysfunction | Liver injury, renal dysfunction markers, respiratory and systemic complications | [127][144][194] |
| Host reserve | Sarcopenia, nutritional status, and timing of enteral nutrition may modify progression | [148][150] |
History and Physical Examination
- ▸Pain is often the presenting symptom of acute pancreatitis and should be characterized comprehensively, scored at baseline, and reassessed serially [156].
- ▸Pain severity may not correlate with structural pancreatic abnormalities, particularly in recurrent acute or chronic pancreatitis [161].
- ▸Review recent procedures, especially ERCP, biliary obstruction, cancer therapy, triglyceride risk, and current medications [72,133,167].
- ▸Consider age, frailty, nutritional decline, muscle weakness, and functional status when assessing severity and prognosis [168,197].
- ▸In children, distinguish hyperamylasemia from pancreatitis and document feeding tolerance, prior episodes, and inflammatory or genetic comorbidity [74,160,196].
- ▸Pregnancy requires explicit assessment of gestational age and maternal-fetal risk [198].
- ▸Physical examination should include organ dysfunction, hydration, abdominal findings, nutrition, mobility, and rehabilitation potential [139,156,168,197].
Presenting symptom and pain history
Pain is frequently the presenting symptom of acute pancreatitis and has prognostic significance; inadequately treated pain may adversely affect patient outcomes [156]. At presentation, document onset, duration, progression, severity, location, radiation, precipitating or relieving factors, associated nausea or vomiting, and the effect of pain on oral intake, mobility, sleep, and function [156]. Record a baseline pain score and reassess it serially, because pain intensity and analgesic requirements may vary during hospitalization [156]. A high serum lipase level has been associated with increased analgesic use in hospitalized patients, although the evidence comes from a single-center retrospective study and does not establish causality [162].
Pain severity should not be assumed to reflect the extent of structural pancreatic disease: patients with recurrent acute or chronic pancreatitis may experience substantial pain despite limited correlation between pain intensity and structural changes [161]C. The history should therefore identify previous acute pancreatitis episodes, persistent or recurrent pain, chronic opioid or analgesic exposure, and functional impairment, while avoiding reliance on pain intensity alone for severity assessment [156][161]C.
Etiologic and precipitating history
The history should establish whether the episode followed an endoscopic or surgical procedure, particularly ERCP, because postprocedural pancreatitis is a recognized adverse event after ERCP [72]. In patients with malignant distal biliary obstruction, EUS-guided choledochoduodenostomy was investigated as an alternative primary drainage procedure to ERCP in individuals with a dilated common bile duct of ≥15 mm, specifically because of concern about postprocedural pancreatitis [72]. Document the indication for the procedure, timing of symptom onset, biliary obstruction, and any prior endoscopic interventions [72].
Ask about gallstone or biliary disease, prior stone clearance, and planned or completed cholecystectomy; a 2026 cohort specifically compared laparoscopic cholecystectomy performed 3–6 hours, at 24 hours, or within 24–72 hours after ERCP for choledocholithiasis [133]. Medication and treatment history should include agents associated with metabolic complications, recent cancer therapy, and antiobesity pharmacotherapy. Severe asparaginase-associated hypertriglyceridemia was defined as triglycerides >1,000 mg/dL in children receiving therapy for acute lymphoblastic leukemia [167]C. Semaglutide and oral orforglipron were evaluated in obese adults with and without diabetes, so current or recent use should be recorded when reviewing the medication history and metabolic context [142][157][200].
Comorbidity, vulnerability, and special populations
Document age, frailty, baseline mobility, sarcopenia risk, nutritional status, and major comorbidities. In a cohort of 1,034 adults, patients were stratified into 18–40, 41–60, and 61–80 years groups, with assessment of organ dysfunction, local complications, interventions, and short-term outcomes [168]. Age should therefore be interpreted together with baseline vulnerability and current organ dysfunction rather than used as an isolated severity marker [168].
Assess recent weight loss, reduced intake, muscle weakness, and loss of independence. Patients with moderately severe or severe acute pancreatitis may develop clinically important changes in body composition and sarcopenia over the short term; one prospective study assessed patients at admission and again after 8 weeks, using handgrip strength and CT-derived skeletal muscle index in accordance with EWGSOP2-related definitions [197]. Baseline body mass index and nutritional trajectory are also relevant when evaluating recovery, because post-intervention BMI changes have been studied in chronic pancreatitis cohorts with painful pancreatic stones [159].
For children, document age, weight, hydration, feeding tolerance, prior episodes, family history, and potential genetic or inflammatory disease associations. Pediatric acute pancreatitis cohorts have used INSPPIRE diagnostic criteria and the 2017 NASPGHAN severity classification [196]. In children with inflammatory bowel disease, hyperamylasemia occurred in 18.6% of the analyzed cohort and was investigated in relation to clinical causes and amylase gene copy-number variation, emphasizing that an elevated amylase value is not synonymous with acute pancreatitis [160]C. In pediatric mild-to-moderately severe pancreatitis, a randomized study compared oral with nasogastric feeding and assessed pain duration, feeding tolerance, and weight change [74]; feeding history should consequently include current intake, vomiting, and tolerance of oral or enteral nutrition [74].
Ask about pregnancy or possible pregnancy in patients of childbearing potential. Acute pancreatitis during pregnancy may affect both maternal and fetal outcomes, and severity was specifically evaluated in a tertiary-center study of pregnant patients [198]. Record gestational age, prior obstetric complications, gallstone disease, metabolic risk factors, and fetal or maternal symptoms requiring urgent assessment [198].
Physical examination
The examination should be structured around pain, hydration and nutritional status, mobility, and evidence of organ dysfunction or local complications, because these domains were central to contemporary studies of pain, age-related vulnerability, sarcopenia, and severe disease [156][168][197]. Record vital signs, mental status, perfusion, respiratory effort, abdominal tenderness and distension, bowel function, jaundice, and the patient’s ability to mobilize and tolerate intake [156][168]. Examine for clinically apparent muscle wasting or weakness and document baseline functional capacity, particularly in older or severely ill patients [168][197].
In severe acute pancreatitis requiring intensive care, prolonged immobilization can produce profound physical deconditioning; a randomized trial therefore evaluated structured early rehabilitation for effects on length of stay, functional recovery, and survival [139]. Functional examination should include mobility, transfers, limb strength, and ability to participate in rehabilitation when clinically safe [139]. Findings should be reassessed alongside pain scores, nutritional intake, and evolving organ dysfunction rather than recorded only at admission [139][156][168].
| Domain | Items to document | Evidence |
|---|---|---|
| Pain | Onset, severity, trajectory, functional effect, analgesic exposure, recurrent or chronic pattern | [156][161]C[162] |
| Etiology/procedure | Biliary disease, ERCP, drainage procedure, choledocholithiasis, cancer therapy | [72][133][167]C |
| Metabolic risk | Hypertriglyceridemia, diabetes, obesity, antiobesity medications | [142][157][167]C[200] |
| Vulnerability | Age, frailty, weight loss, intake, weakness, sarcopenia, baseline mobility | [168][197] |
| Special populations | Pediatric criteria and feeding tolerance; pregnancy and gestational age | [74][160]C[196][198] |
| Examination | Vital status, abdominal findings, hydration, nutrition, organ dysfunction, mobility | [139][156][168][197] |
Supportive Care and Complication Management
- ▸The supplied meta-analysis found no mortality difference between lactated Ringer’s and normal saline (OR 1.020) [169].
- ▸Early enteral nutrition was studied when initiated within 48 hours, but the supplied abstract does not provide effect estimates [150].
- ▸HTG-AP is heterogeneous; LMWH effects may differ by subphenotype, and the supplied abstract does not report subgroup results [170].
- ▸An early triglyceride target of ≤5.65 mmol/L within 72 hours was not associated with differences in pancreatic necrosis or hospital outcomes in the supplied retrospective study [113].
- ▸WOPN and IPN require multidisciplinary management; current supplied abstracts do not provide enough procedural detail to rank drainage or necrosectomy techniques [202,205].
- ▸Splanchnic-vein thrombosis anticoagulation requires individualized assessment of thrombosis location and bleeding risk [175].
Initial supportive care
Acute pancreatitis (AP) management should be individualized according to disease severity, organ dysfunction, etiology, fluid status, and evolving complications; the supplied evidence does not establish a single universal resuscitation volume or infusion rate. A five-year retrospective study specifically evaluated intravenous-fluid dose and rate during the first 24 hours after admission, including systemic complications and prognosis, but the supplied abstract does not provide the outcome estimates needed to define a target regimen [181].
A 2026 systematic review and meta-analysis comparing lactated Ringer’s (LR) with normal saline (NS) evaluated mortality, systemic inflammatory response syndrome (SIRS), intensive-care transfer, pancreatic necrosis, organ failure, and hospital length of stay. Overall mortality did not differ between LR and NS (OR 1.020, 95% CI not fully reported in the supplied abstract) [169]. Accordingly, the available supplied evidence supports that mortality superiority of LR over NS has not been demonstrated, while other comparative outcomes cannot be quantified from the provided abstract [169].
Nutritional support is a major component of supportive management. A retrospective study of 1,600 patients evaluated early enteral nutrition (EN), defined as initiation within 48 hours, versus delayed EN, with adjustment for demographic characteristics, body mass index, etiology, and comorbidities; the study also examined nutritional status, metabolic and inflammatory biomarkers, gut-barrier markers, organ failure, and mortality [150]. Because the supplied abstract does not report the adjusted effect estimates, it should not be used alone to prescribe a specific feeding route or regimen [150].
Hypertriglyceridemic acute pancreatitis
Hypertriglyceridemic AP (HTG-AP) is clinically heterogeneous. A prospective cohort of 1,483 patients used admission clinical and laboratory variables to identify subphenotypes and validated them in a multicenter randomized trial of 533 patients examining differential responses to low-molecular-weight heparin (LMWH) [170]. The supplied abstract does not provide the subgroup-specific treatment effects; therefore, LMWH should not be considered uniformly beneficial for all patients with HTG-AP on the basis of this evidence alone [170].
A retrospective study of 345 patients defined early triglyceride-goal achievement as triglycerides ≤5.65 mmol/L within 72 hours of admission and assessed associations with necrosis, hospitalization, and severity outcomes; the supplied abstract reports no significant difference in pancreatic necrosis or hospital outcomes between patients who did and did not achieve this goal [113]. These findings do not establish that failure to reach the threshold requires a particular rescue therapy [113].
Necrosis, collections, and infection
Symptomatic walled-off pancreatic necrosis (WOPN) is a serious sequela of AP associated with substantial morbidity and mortality. The 2026 SAGES guideline used a systematic review of studies published from 1 January 2020 through 24 January 2025, followed by multidisciplinary GRADE-based recommendations involving surgeons, gastroenterologists, and interventional radiologists from SAGES and AHPBA [202]. Management should therefore be multidisciplinary and directed at symptoms, infection, obstruction, and clinical deterioration; the supplied abstract does not include the individual procedural recommendations or certainty ratings [202].
In suspected infected pancreatic necrosis (IPN), microbiology may vary with timing and testing method. In a prospective study of 20 patients undergoing first percutaneous catheter drainage, metagenomic next-generation sequencing (mNGS) detected organisms in 45.0% of samples (9/20), compared with 30.0% by conventional culture (6/20); samples were compared according to disease onset ≤14 versus >14 days, although the supplied abstract does not provide the time-stratified results [172]. Drainage-fluid microbiology should therefore be interpreted in the context of clinical course, timing, and test limitations [172].
After failed conservative treatment and percutaneous catheter drainage, a retrospective cohort of 107 patients with SAP-related IPN compared robot-assisted pancreatic necrosectomy (RAPN; n=26), conventional minimally invasive surgery (n=47), and open necrosectomy (n=34) [205]. Baseline characteristics did not differ significantly among groups, and RAPN had a longer operative time than conventional minimally invasive surgery and open surgery; the supplied abstract does not report complete comparative efficacy or safety estimates [205]. Video-assisted retroperitoneal debridement (VARD) was also described in a retrospective, uncontrolled case series of 41 patients using a standardized perioperative nursing protocol [177]C. These data support experienced multidisciplinary and perioperative care but do not establish superiority of one necrosectomy approach [177]C[205].
Vascular, abdominal, and unusual complications
In necrotizing pancreatitis complicated by splanchnic-vein thrombosis, a retrospective study of 529 patients identified thrombosis in 73 (13.8%); 47.9% involved the splenic vein and 52.1% the portomesenteric veins [175]. Portomesenteric thrombosis was associated with greater anticoagulant use (50% versus 17.1%) and bleeding interventions (24%, with the comparator value not included in the supplied abstract) [175]. Anticoagulation decisions should therefore balance thrombus location, progression, recanalization potential, and bleeding risk rather than follow an automatic rule [175].
Early risk tools remain investigational. Peak D-dimer within 24 hours of admission was evaluated as a predictor of IPN in 286 patients with hyperlipidemic AP, including 47 with IPN, with temporal validation in an additional 62 patients [204]. Automated CT volumetry of peripancreatic collections was developed and externally tested in 394 patients from multiple centers to assess early risk stratification [174]. Neither study, based on the supplied abstracts, provides sufficient evidence to replace clinical assessment or validated severity classifications [174][204].
Rare complications require urgent specialist evaluation. A reported case involved pancreaticoportal fistula with portal-vein thrombosis, infected collections, cutaneous necrosis, septic shock, and multiple-organ failure [184]C. Another case described carbapenem-resistant Acinetobacter baumannii IPN with concurrent Enterococcus faecium bacteremia, persistent organ failure, abdominal-compartment syndrome, acute kidney injury requiring continuous renal-replacement therapy, and salvage treatment with sulbactam-durlobactam plus tigecycline [183]C. These reports are hypothesis-generating and cannot define routine antimicrobial therapy [183]C[184]C.
Evidence outside routine adult AP care includes a pediatric retrospective series in which EUS-guided drainage of symptomatic pseudocysts or WOPN was assessed using lumen-apposing metal stents or double-pigtail plastic stents [206]C. The findings should not be directly generalized to adults [206]C. EUS-guided hepaticogastrostomy evidence concerned unresectable malignant biliary obstruction rather than AP and is not applicable to routine pancreatic-fluid-collection management [125]. Cytokine profiling, mirabilite external dressing, and abdominal drainage remain investigational or limited by retrospective designs, single-center samples, or uncontrolled comparisons [179][193].
| Topic | Threshold or population | Evidence implication |
|---|---|---|
| Fluid resuscitation | First 24 hours | Dose and rate were evaluated retrospectively; no supplied target was reported [181]. |
| Enteral nutrition | Within 48 hours | Early versus delayed EN was evaluated in 1,600 patients; effect estimates were not supplied [150]. |
| Triglyceride reduction | ≤5.65 mmol/L within 72 hours | No significant difference in pancreatic necrosis or hospital outcomes was reported between goal-achieved and non-achieved groups [113]. |
| IPN risk assessment | D-dimer within 24 hours | Retrospective model in 286 patients with temporal validation in 62 [204]. |
| Drainage microbiology | Disease onset ≤14 versus >14 days | mNGS positivity was 45.0% and culture positivity 30.0% overall [172]. |
| WOPN evidence | Literature from 2020–2025 | Multidisciplinary SAGES/AHPBA guideline development using GRADE [202]. |
References
- [1]
Vujasinovic M, Demir IE, Marchegiani G et al.. “International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.” United European gastroenterology journal (2026). PMID: 41689768 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Adeniran EA, Jiang Y, Yadav D et al.. “Multiple substance use and the risk of pancreatitis: a systematic review.” Therapeutic advances in gastroenterology (2025). PMID: 40873658 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heo D, Cardoso SA, Cardoso RP et al.. “Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis.” Surgery (2025). PMID: 40435914 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Kowal MR, Bhatnagar V, Pine J et al.. “Systematic review of peritoneal lavage and dialysis for patients with severe acute pancreatitis.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 39939210 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Williamson L, Hao Y, Basnayake C et al.. “Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2024). PMID: 39461088 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Haseef M, Li SCH, Gaitt T et al.. “Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.” Current opinion in endocrinology, diabetes, and obesity (2026). PMID: 41717773 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [7]
Ibrahim MY, Alhaj MM, Ibrahim AAA et al.. “Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.” BMC gastroenterology (2025). PMID: 41388444 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [8]
Kuzman M, Joseph N, Nafady R et al.. “Clinical Impact of Sarcopenia and Sarcopenic Obesity in Acute Pancreatitis: A Systematic Review.” ANZ journal of surgery (2026). PMID: 41351308 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, History and Physical Examination - [9]
Siuka D, Rakuša M, Vodenik A et al.. “Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective Study.” International journal of molecular sciences (2025). PMID: 40565159 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Yahia Y, Abuodeh J, Chandra P et al.. “Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.” Obesity surgery (2025). PMID: 39806256 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Blažević N, Trkulja V, Rogić D et al.. “YKL-40 as a risk stratification marker in acute pancreatitis: A prospective study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 39638701 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A et al.. “Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol.” Trials (2024). PMID: 39434191 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [13]
Grudzińska E, Gajda M. “Postoperative Acute Pancreatitis After Pancreatic Resections-A Narrative Review and a Diagnostic Algorithm.” Cancers (2025). PMID: 40940873 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sato A, Tani A, Mishima Y et al.. “Assessment of two different criteria for post-pancreatectomy acute pancreatitis: a single-center retrospective analysis and literature review.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40340215 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bouça-Machado T, Araújo Teixeira JP, Rebelo P et al.. “Comparison of acute pancreatitis and acute on chronic pancreatitis: a retrospective cohort study.” European journal of gastroenterology & hepatology (2025). PMID: 39976002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [16]
Ranjan MK, Neupane P, Maharjan B et al.. “Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.” Gastroenterology research and practice (2026). PMID: 41971243 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [17]
Zhou H, Li W, Yang S et al.. “Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study.” Medicine (2025). PMID: 40629608 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [18]
Orbelian L, Trembach N, Durleshter V. “The Role of Inflammatory and Hemostatic Markers in the Prediction of Severe Acute Pancreatitis: An Observational Cohort Study.” Recent advances in inflammation & allergy drug discovery (2025). PMID: 39694959 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [19]
Dungan KM, Chinchilli VM, Pichardo-Lowden A et al.. “Hyperglycemia During Acute Pancreatitis and Progression to Early-Onset Diabetes After Recovery: Preliminary Findings From the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study.” Diabetes care (2026). PMID: 41940812 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Poelsler LH, Bellotti R, Pably D et al.. “Analysis of Different Post-Operative Hyperamylasemia Criteria for Defining Post-Pancreatectomy Acute Pancreatitis After Distal Pancreatectomy-A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 41827220 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Emara A, Mansour A, Aboeldahab H et al.. “Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41943994 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [22]
Elbahloul MA, Gamal A, Maihoub O et al.. “Efficacy and Safety of Apolipoprotein C-III Inhibitors in Hypertriglyceridemia: A Network Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41917770 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [23]
Rehman A, Rajdeep D, Mohnkern JD et al.. “Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Digestive diseases and sciences (2026). PMID: 41865223 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [24]
Peterson AL, Ashraf AP, Bachman J et al.. “Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41705332 ↗
L1cGUIDELINECited in: Etiology and Triggering Factors - [25]
Masood A, Qureshi AUH, Khalid Z et al.. “Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2026). PMID: 41755797 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [26]
Loomba R, de-Madaria E, Afghani E et al.. “Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41923352 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [27]
Qi S, Wang S, Chen W et al.. “Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: A 10-year triglyceride-stratified retrospective study.” Journal of clinical lipidology (2026). PMID: 41963121 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [28]
Cerbino B, Süffert LC, Monteiro A et al.. “Intrapancreatic Fat Deposition and Risk of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis.” Pancreas (2026). PMID: 41668341 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [29]
Shi B, Feng J, Hu P et al.. “Clinical Outcomes and Safety of Ureteral Catheter-Assisted Antegrade Guidewire Intubation in the Laparoscopic-Endoscopic Rendezvous Procedure for Cholelithiasis with Choledocholithiasis: A Retrospective Cohort Study.” Therapeutics and clinical risk management (2026). PMID: 41859199 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [30]
Liu J, Xu H, Huang C et al.. “Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study.” Frontiers in nutrition (2026). PMID: 41693951 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [31]
Dayan-Rosenman D, Diletti-Swenson S, Ghayalod N et al.. “Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.” Addiction science & clinical practice (2026). PMID: 41680940 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [32]
Maringhini A, Patti R, Maringhini M et al.. “Ursodeoxycholic Acid for the Prevention of Relapse of Pregnancy-Related Acute Gallstone Pancreatitis.” Journal of clinical medicine (2026). PMID: 41976880 ↗
L5OTHERCited in: Etiology and Triggering Factors - [33]
Deng F, Ding L, Du YY et al.. “Low-molecular-weight heparin and respiratory failure in hypertriglyceridemia-associated acute pancreatitis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41968002 ↗
L5OTHERCited in: Etiology and Triggering Factors - [34]
Li Y, Wang Y, Wan X et al.. “Radiomics derived from MRI T2-weighted imaging combined with clinical variables for predicting disease severity in hypertriglyceridemic acute pancreatitis.” Abdominal radiology (New York) (2026). PMID: 41925844 ↗
L5OTHERCited in: Etiology and Triggering Factors - [35]
Sirtl S, Ahmad M, Allawadhi P et al.. “NLRP3 Inflammasome Activation-Induced Acute Papillitis as a Trigger of Acute Pancreatitis - A Novel Mechanism of Microlithiasis-Induced Acute Pancreatitis.” United European gastroenterology journal (2026). PMID: 41830600 ↗
L5OTHERCited in: Etiology and Triggering Factors - [36]
Ozkaya M, Atik I, Ozkaya S et al.. “Incidence and clinical significance of biliary and pancreatic duct variations on magnetic resonance cholangiopancreatography.” Abdominal radiology (New York) (2026). PMID: 41801378 ↗
L5OTHERCited in: Etiology and Triggering Factors - [37]
Faraci S, Rollo G, Alghisi F et al.. “ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41723027 ↗
L5OTHERCited in: Etiology and Triggering Factors - [38]
Liu Z, He Y, Chen Z et al.. “Pleural effusion within 24 h of admission predicts severe hypertriglyceridemia-induced acute pancreatitis and organ failure: retrospective cohort of 296 patients.” Frontiers in medicine (2026). PMID: 41658612 ↗
L5OTHERCited in: Etiology and Triggering Factors - [39]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L5OTHERCited in: Etiology and Triggering Factors - [40]
Spoială EL, Oltean C, Vasiliu I et al.. “Multimodal Management of Extreme Hypertriglyceridemia in a Child with Recurrent Pancreatitis: Clinical Challenges and Solutions.” Journal of clinical medicine (2026). PMID: 41598575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [41]
Krajewska A, Tłustochowicz K, Kowalik A et al.. “Comparison of the Clinical Course, Management and Outcomes of Acute Pancreatitis in Aged and Young Patients.” Biomedicines (2026). PMID: 41595672 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [42]
Chiriac S, Sfarti C, Minea H et al.. “Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Bile Duct Stones-Avoiding the Avoidable.” Biomedicines (2026). PMID: 41595627 ↗
L5OTHERCited in: Etiology and Triggering Factors - [43]
Choudhary A, James A, Dahake U et al.. “Therapeutic plasmapheresis in a young infant with severe hypertriglyceridemia: a case report.” Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology (2026). PMID: 41923786 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [44]
Takasu S, Nakagawa M, Matsumoto S. “Autopsy case of a possible enigmatic triad accompanied by black esophagus and Wischnewsky spots.” Legal medicine (Tokyo, Japan) (2026). PMID: 41774981 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [45]
Vega J, Torres B, Maiz A et al.. “Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.” Frontiers in nutrition (2026). PMID: 41737337 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Bodnar C, Hughey C, Bodker A et al.. “Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia-Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction.” Journal of clinical apheresis (2026). PMID: 41709485 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Liu T, Cao Z, Lai F et al.. “Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols.” Frontiers in pediatrics (2025). PMID: 41602884 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [48]
Wang Z, Liu Y, Ren P et al.. “A prognostic model based on metabolic indicators for recurrent acute pancreatitis in hypertriglyceridemia patients: a retrospective cohort study.” Annals of medicine (2026). PMID: 41978916 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [49]
Gondal AN, Ahmed P, Akram F et al.. “Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.” Cureus (2026). PMID: 41646617 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [50]
Popa SL, Incze V, Ismaiel A et al.. “Non-Infectious Causes for Elevated Procalcitonin.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901546 ↗
L2aSR_OBSCited in: Pathophysiology - [51]
Yang X, Zhang L, Lin H et al.. “Early oral anti-inflammatory diet in patients with mild acute pancreatitis: study protocol for a randomized controlled trial.” Trials (2026). PMID: 41668182 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [52]
Yan H, Dang X, Du G et al.. “IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential.” Frontiers in immunology (2026). PMID: 41737213 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [53]
Tun HN, Rahal O, Figueroa Baez IR et al.. “Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.” ESC heart failure (2026). PMID: 41711215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [54]
Zhang J, Chen H, Wang Y et al.. “Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41663764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [55]
Kurt SZE, Kurt E, Isin MS et al.. “The diagnostic value of the systemic immune-inflammation index in acute pancreatitis: a retrospective cohort study.” Irish journal of medical science (2026). PMID: 41926028 ↗
L2bCOHORTCited in: Pathophysiology - [56]
Ma H, Li N, Zhang H et al.. “The association between inflammatory indices and acute pancreatitis severity: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 41835252 ↗
L2bCOHORTCited in: Pathophysiology - [57]
Chooklin S, Chuklin S. “Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.” Discover nano (2026). PMID: 41661463 ↗
L2aSR_OBSCited in: Pathophysiology - [58]
Wang Y, Ma L, Jiang Y et al.. “Revealing the temporal metabolic trajectory and potential pharmacodynamic substances of Da-Cheng-Qi Decoction in treating patients with acute pancreatitis: A serum metabolomics-based study.” Journal of ethnopharmacology (2026). PMID: 41825726 ↗
L1bRCTCited in: Pathophysiology - [59]
Alsaleh T, George J. “Targeted therapeutics for pancreatitis.” Frontiers in physiology (2026). PMID: 41907532 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Chooklin S, Chuklin S. “Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 41854947 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Chooklin S, Chuklin S. “Interleukin-22 in acute pancreatitis: Balancing damage and repair.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41763954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [62]
Chooklin S, Chuklin S. “Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.” Digestive diseases and sciences (2026). PMID: 41703270 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Dai NN, Geng ZG, Wang J et al.. “Pancreas-brain axis: exploring the pathogenic mechanisms of pancreatic encephalopathy.” International immunopharmacology (2026). PMID: 41689875 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Feng X, Lin J. “Advances in Glucocorticoid Therapy for Acute Pancreatitis: A Review.” Pancreas (2026). PMID: 41677367 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Xu K, Han Y, Chen F et al.. “Dose-dependent dissociation between intestinal protection and pancreatic outcome following licochalcone A treatment in severe acute pancreatitis.” Frontiers in pharmacology (2026). PMID: 41971086 ↗
L5OTHERCited in: Pathophysiology - [66]
Li H, Zhang X, He Z et al.. “Disruption of the Circadian Rhythm Induces Acute Pancreatitis via Amino Acid Metabolism-Mediated Macrophage Infiltration.” Cellular and molecular gastroenterology and hepatology (2026). PMID: 41903683 ↗
L5OTHERCited in: Pathophysiology - [67]
Guan L, Li X, He C et al.. “Bifidobacterium Pseudolongum-Derived Acetate Attenuates Acute Pancreatitis Through GPR43-Mediated Suppression of M1 Macrophage Polarization.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41903115 ↗
L5OTHERCited in: Pathophysiology - [68]
Uppal M, Neredimelli SK, Yadav HN et al.. “Development of an experimental model of severe acute pancreatitis with organ failure.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41881753 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [69]
Cheng L, Jiang C, Jiang W et al.. “Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 41877788 ↗
L5OTHERCited in: Pathophysiology - [70]
Joseph N, Kuhlmann L, Lucocq J et al.. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomized Controlled Trials.” Pancreas (2026). PMID: 40748823 ↗
L1aSR_MA_RCTCited in: History and Physical Examination - [71]
Dobszai D, Obeidat M, Szalai EÁ et al.. “Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41262260 ↗
L2aSR_OBSCited in: History and Physical Examination - [72]
Anderloni A, Spadaccini M, Binda C et al.. “Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.” Gastroenterology (2026). PMID: 41511419 ↗
L1bRCTCited in: History and Physical Examination - [73]
Gan W, Zhang W, Cai J et al.. “A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015.” Cancer medicine (2025). PMID: 40842042 ↗
L1bRCTCited in: History and Physical Examination - [74]
Han Y, Zhao H, Fu L et al.. “The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study.” Jornal de pediatria (2026). PMID: 41620210 ↗
L1bRCTCited in: History and Physical Examination - [75]
Wan J, Xiong S, Zou Y et al.. “Cumulative burden and dynamic trajectories of heart rate as predictors of prognosis in acute pancreatitis: an 18-year cohort study.” International journal of surgery (London, England) (2026). PMID: 40990508 ↗
L2bCOHORTCited in: History and Physical Examination - [76]
Kerbage A, Brunaldi VO, Al Annan K et al.. “Impact of Metabolic Surgery on the Severity and Outcomes of Acute Pancreatitis: A Retrospective Matched Cohort Study.” Obesity surgery (2025). PMID: 40804224 ↗
L2bCOHORTCited in: History and Physical Examination - [77]
Palermo TM, Ohls O, Dear B et al.. “Digital cognitive-behavioral therapy for pain management in individuals with recurrent acute and chronic pancreatitis (IMPACT-2): study protocol for a hybrid effectiveness-implementation trial.” Trials (2026). PMID: 41664170 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [78]
Jalleh RJ, Talley NJ, Horowitz M et al.. “The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.” The Journal of clinical investigation (2026). PMID: 41697736 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [79]
Tayier D, Wang K, Yuan Y et al.. “Research Status on the Effects of Obesity on Acute Pancreatitis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 40751382 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [80]
Wang YX, Ge P, Chen HL. “Induction of hyperlipidemic pancreatitis by different fatty acids: A narrative review.” World journal of gastroenterology (2025). PMID: 40539203 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [81]
Zhu Q, Shan X, Tan D et al.. “Risk factor analysis and nomogram development for survival prediction in obese patients with severe acute pancreatitis: a retrospective study.” BMC gastroenterology (2025). PMID: 41013263 ↗
L2bCOHORTCited in: History and Physical Examination - [82]
Jaya Pragadeesh G, Abu Sali SA, Rajesh Kumar S et al.. “Gliptin induced acute pancreatitis: a literature review.” Acta gastro-enterologica Belgica (2025). PMID: 40504582 ↗
L2aSR_OBSCited in: History and Physical Examination - [83]
Mohamadnejad M, Hassanzadeh M, Anushirvani A et al.. “Immediate vs On-Demand Endoscopic Necrosectomy in Infected Walled-Off Pancreatic Necrosis: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41722664 ↗
L1bRCTCited in: Supportive Care and Complication Management - [84]
Eperjesi O, Bucur M, Rancz A et al.. “Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41807143 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [85]
Chooklin S, Chuklin S. “Neutrophil-to-lymphocyte ratio for primary risk stratification in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41608433 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [86]
Ren Y, Xia L, Luo L et al.. “Early direct admission to tertiary hospital specialized care reduces risk of severe acute pancreatitis: A propensity score-matched retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41692636 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [87]
Xu X, He C, Ding L et al.. “The similarity between microbiota of gut and pancreatic necrotic drainage fluid in infected pancreatic necrosis and its potential diagnostic value: a prospective observational cohort study.” BMC microbiology (2026). PMID: 41612182 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [88]
Shahzil M, Faisal MH, Khan MH et al.. “Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41925047 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [89]
Shakeev K, Klyuyev D, Ogizbayeva A et al.. “Comparative Evaluation of the Prognostic Accuracy of IL-6 and Angiopoietin-2 for Early Severity Assessment in Acute Pancreatitis: A Systematic Review.” Diseases (Basel, Switzerland) (2026). PMID: 41590239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [90]
Qi R, Zhong J, Wang H et al.. “Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.” Journal of inflammation research (2026). PMID: 41982474 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [91]
Lew C, Jones M, Pham H et al.. “Outcomes of Patients With Severe Acute Pancreatitis Requiring Prolonged Intensive Care Admission at a Tertiary Centre: A Retrospective Cohort Study.” ANZ journal of surgery (2026). PMID: 41823127 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [92]
Cao Y, Li W, Peng P et al.. “Development and validation of an early prediction model for hypertriglyceridaemic severe acute pancreatitis: a retrospective study.” PeerJ (2026). PMID: 41584837 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [93]
Xu H, Zhang Z, Yang Y et al.. “Partial hepatectomy for pancreatic-origin hepatic abscess with intracystic hemorrhage following severe acute pancreatitis: a case report.” Frontiers in medicine (2026). PMID: 41868209 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [94]
Iacob A, Balan GG, Blaj M et al.. “Fungal Infections in Severe Acute Pancreatitis: Insights from a Case Series.” Journal of clinical medicine (2026). PMID: 41598727 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [95]
Tsuyama T, Suenaga S, Suehiro H et al.. “Lumen-apposing metal stent for peripancreatic fluid collection contributes to early improvement of nutritional status: A multicenter retrospective study (YCR-P001).” Medicine (2026). PMID: 41824843 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [96]
Zhang X, Peng K, Peng Y et al.. “Serum GAS6 is useful biomarker for identifying patients with severe acute pancreatitis within 24 h of admission: a multi-cohort analysis of 869 patients.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41956867 ↗
L5OTHERCited in: Supportive Care and Complication Management - [97]
Feng H, Wang P, He W et al.. “Development and interpretable machine learning models for classification of pancreatic pseudocyst risk in acute pancreatitis.” Frontiers in digital health (2026). PMID: 41924180 ↗
L5OTHERCited in: Supportive Care and Complication Management - [98]
Zhu P, Fang W, Tu H. “Development and validation of a nomogram model for predicting unplanned readmission in patients with acute pancreatitis.” Frontiers in endocrinology (2026). PMID: 41890191 ↗
L5OTHERCited in: Supportive Care and Complication Management - [99]
Lu H, Shen H, Cui J et al.. “Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.” Chinese medical journal (2026). PMID: 41859859 ↗
L5OTHERCited in: Supportive Care and Complication Management - [100]
Pauw HS, Schwarz R, Beij A et al.. “Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics.” The Journal of antimicrobial chemotherapy (2026). PMID: 41808660 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [101]
Kitagawa K, Asada S, Hanatani JI et al.. “Multi-Hole Self-Expandable Metallic Stent for Malignant Distal Biliary Obstruction: A Literature Review.” Journal of clinical medicine (2026). PMID: 41753098 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [102]
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L et al.. “Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750517 ↗
L5OTHERCited in: Supportive Care and Complication Management - [103]
Yamashita Y, Kitano M. “EUS-guided pancreatic duct drainage-technical tips and outcomes: narrative review.” Therapeutic advances in gastroenterology (2026). PMID: 41732329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Ma S, Qin J, Luan J et al.. “Targeting mitochondrial phosphatase PGAM5 alleviates ferroptosis and acute pancreatitis by upregulating NRF2-mediated FSP1 expression.” Cell death & disease (2026). PMID: 41723122 ↗
L5OTHERCited in: Supportive Care and Complication Management - [105]
Siriwardena AK. “A Practical Guide to the Roles of Procalcitonin Measurement in Patients with Acute Pancreatitis.” Journal of clinical medicine (2026). PMID: 41682834 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Cárdenas-Jaén K, Guilabert L, Martínez-Moneo E et al.. “AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).” United European gastroenterology journal (2026). PMID: 42216617 ↗
L1aCited in: Definition, Synonyms, and Classification - [107]
Kudchadkar S, Peddakota V, Mudavath LC et al.. “Systematic Review of Role of Oxidative Stress and Clinical Implications in Acute Pancreatitis.” World journal of surgery (2026). PMID: 42438222 ↗
L2aCited in: Definition, Synonyms, and Classification - [108]
Wang F, Huang Z, Xue Z et al.. “APEX-NET: automated pancreatic evaluation network using early non-contrast CT.” European radiology (2026). PMID: 42377437 ↗
L2bCited in: Definition, Synonyms, and Classification - [109]
Madela F, Chiliza K, Mfeka X et al.. “Correlation between immune biomarkers and surrogate markers of severity of Acute Pancreatitis in an HIV endemic region.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 41314904 ↗
L2bCited in: Definition, Synonyms, and Classification - [110]
Hubert MO, Ahmad M, Crispin A et al.. “Meta-Analysis Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 42139165 ↗
L2aCited in: Definition, Synonyms, and Classification - [111]
Rantsev M, Sarapultsev A, Chereshnev V. “Neuromodulatory Interventions in Experimental Acute Pancreatitis: A Systematic Review of Rodent Studies.” Diseases (Basel, Switzerland) (2026). PMID: 42041637 ↗
L2aCited in: Definition, Synonyms, and Classification - [112]
Yavuz A, Ebik B, Karabulut Ü et al.. “Evaluation of the Admission Neutrophil Percentage-to-Albumin Ratio for Predicting the Severity of Acute Pancreatitis.” Biomedicines (2026). PMID: 42512016 ↗
L3bCited in: Definition, Synonyms, and Classification - [113]
Yu M, Mao E, Xu Y et al.. “Triglyceride Threshold for Intensive Lipid-Lowering Therapy in Acute Hyper-Triglyceridemic Pancreatitis: A Retrospective Study.” Journal of clinical medicine (2026). PMID: 42355749 ↗
L3bCited in: Definition, Synonyms, and Classification - [114]
Wei W, Wang Y, Xie P et al.. “Development of a prediction method for severe pancreatitis using a nomogram.” Frontiers in medicine (2026). PMID: 42180752 ↗
L3bCited in: Definition, Synonyms, and Classification - [115]
Chiarello MM, Fico V, Misuriello F et al.. “Are BISAP and APACHE II scores still useful to identify high-risk patients in acute pancreatitis? A retrospective multicenter analysis on 450 patients.” Updates in surgery (2026). PMID: 42166093 ↗
L3bCited in: Definition, Synonyms, and Classification - [116]
Hao X, Feng X, Liu F et al.. “Real-time guidance of lauromacrogol ablation for pancreatic cystic lesions using confocal laser endomicroscopy.” Therapeutic advances in gastroenterology (2026). PMID: 41705165 ↗
L3bCited in: Definition, Synonyms, and Classification - [117]
Xu X, Xu T, Wang Y et al.. “Clinical value of BISAP score combined with low-density lipoprotein cholesterol and ascites in early prediction of hypertriglyceridemic severe acute pancreatitis.” Frontiers in endocrinology (2025). PMID: 41446633 ↗
L3bCited in: Definition, Synonyms, and Classification - [118]
Saullo P, Caronna R, Angelici AM et al.. “Value of Continuous Hemofiltration in Patients with Severe Acute Pancreatitis at Onset: Single Centre Experience on 48 Patients.” Journal of clinical medicine (2025). PMID: 41010851 ↗
L3bCited in: Definition, Synonyms, and Classification - [119]
Masson W, Lobo M, Mansur M et al.. “Clinical effects of apolipoprotein C3 inhibitors on triglyceride levels and pancreatitis risk: a systematic review and meta-analysis.” Minerva endocrinology (2026). PMID: 42329673 ↗
L1aCited in: Etiology and Triggering Factors - [120]
Liang AC, Castillo YC, Bruciaga LMM et al.. “Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis.” Digestive diseases and sciences (2026). PMID: 42301369 ↗
L1aCited in: Etiology and Triggering Factors - [121]
Gad MM, Ayad Q, Elgamal MM et al.. “Cholecystectomy versus conservative management for patients with uncomplicated symptomatic gallstones and cholecystitis: an updated systematic review and meta-analysis.” BMC surgery (2026). PMID: 42265664 ↗
L1aCited in: Etiology and Triggering Factors - [122]
Shen Y, Bai Y. “Rectal Nonsteroidal Anti-Inflammatory Drugs, Aggressive Hydration With Lactated Ringer's Solution, Somatostatin or Combinations for Prophylaxis Post-ERCP Acute Pancreatitis: A Network Meta-Analysis.” Pancreas (2026). PMID: 42240446 ↗
L1aCited in: Etiology and Triggering Factors - [123]
Soran H, Kessler AS, Vera-Llonch M et al.. “Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.” Journal of comparative effectiveness research (2026). PMID: 42319369 ↗
L1bCited in: Etiology and Triggering Factors - [124]
Tarar ZI, Gandhi M, Farooq U et al.. “Prophylactic biliary stenting post-ERCP prior to cholecystectomy: a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42443680 ↗
L2aCited in: Etiology and Triggering Factors - [125]
Shaaban Abdelgalil M, Abdelrazek A, Mohamed MS et al.. “EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.” BMC gastroenterology (2026). PMID: 42436411 ↗
L2aCited in: Etiology and Triggering Factors - [126]
Liu J, Yu Y, Qiu X et al.. “Baseline current smoking and time-varying recurrence risk after first-episode of hypertriglyceridemia-induced acute pancreatitis: A multicenter retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42570923 ↗
L3bCited in: Etiology and Triggering Factors - [127]
Li J, Liu X, Zhao R et al.. “Analysis of the association between the neutrophil-to-lymphocyte ratio (NLR) and liver injury complicating acute pancreatitis: a retrospective study.” Frontiers in medicine (2026). PMID: 42559316 ↗
L3bCited in: Etiology and Triggering Factors - [128]
Ain Q, Huda NU, Khan M et al.. “Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study.” Journal of clinical lipidology (2026). PMID: 42538190 ↗
L3bCited in: Etiology and Triggering Factors - [129]
Uemura S, Iwashita T, Koizumi T et al.. “Visceral Adipose Tissue as an Independent Predictor of Severe Post-ERCP Pancreatitis: A Multicenter Retrospective Cohort Study.” Journal of hepato-biliary-pancreatic sciences (2026). PMID: 42494284 ↗
L3bCited in: Etiology and Triggering Factors - [130]
Yang S, Li C, Zeng K et al.. “Development and validation of a 24-h predictive model for hypertriglyceridemic moderately severe acute pancreatitis: a single-center retrospective study.” Frontiers in medicine (2026). PMID: 42465082 ↗
L3bCited in: Etiology and Triggering Factors - [131]
Selin D, Oskarsson V, Maret-Ouda J et al.. “Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis.” JAMA surgery (2026). PMID: 42340741 ↗
L3bCited in: Etiology and Triggering Factors - [132]
Guo Q, Chen W, Qin K et al.. “Integrating 2.5D multi-modal CT imaging with serum triglycerides for early risk stratification in hypertriglyceridemia-induced acute pancreatitis: A multicenter study.” European journal of radiology (2026). PMID: 42322722 ↗
L3bCited in: Etiology and Triggering Factors - [133]
Liu Z, Li Z, Liu D et al.. “Clinical outcomes of immediate, 24-h, and 24-72-h laparoscopic cholecystectomy after endoscopic stone clearance: a matched cohort analysis.” Surgical endoscopy (2026). PMID: 42257960 ↗
L3bCited in: Etiology and Triggering Factors - [134]
Liu F, Liu XQ, Gu DJ et al.. “Laparoscopic common bile duct exploration and primary suture versus ERCP combined with laparoscopic cholecystectomy for choledocholithiasis: a retrospective comparative study.” Surgical endoscopy (2026). PMID: 42257936 ↗
L3bCited in: Etiology and Triggering Factors - [135]
An J, Zhang G, Zhou X. “A prognostic model based on integrated clinical indicators for recurrent acute pancreatitis in patients with hypertriglyceridemia: a retrospective cohort study.” Lipids in health and disease (2026). PMID: 42249448 ↗
L3bCited in: Etiology and Triggering Factors - [136]
Yao W, Zhao C, Cao L et al.. “Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study.” Journal of inflammation research (2026). PMID: 42375817 ↗
L2bCited in: Etiology and Triggering Factors - [137]
Zhao G, Wang Y, Zhang G et al.. “Risk factors for post-ERCP pancreatitis and assessment of stent exchange intervals in children with chronic pancreatitis: a single-center retrospective study.” BMC pediatrics (2026). PMID: 42343307 ↗
L2bCited in: Etiology and Triggering Factors - [138]
Nishimura M, Miwa H, Kaneko T et al.. “Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.” DEN open (2026). PMID: 42569438 ↗
L4Cited in: Etiology and Triggering Factors - [139]
Wang L, Nie Z, Huang Q. “Effect of a structured early rehabilitation program on long-term functional recovery, quality of life, and survival in patients with severe acute pancreatitis: a randomized controlled trial.” BMC gastroenterology (2026). PMID: 42204448 ↗
L1bCited in: Pathophysiology - [140]
Tian H, Wang L, He Z et al.. “Global landscape and knowledge structure of research on pancreatitis and gut microbiota: a bibliometric analysis based on WoSCC and Scopus (2006 - 2025).” Frontiers in cellular and infection microbiology (2026). PMID: 42568357 ↗
L2aCited in: Pathophysiology - [141]
Pakai E, Klonfar K, Walter A et al.. “Fever on hospital admission is associated with increased disease severity and mortality in acute pancreatitis: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42482129 ↗
L2aCited in: Pathophysiology - [142]
Naz F, Qaiser F, Mumtaz A et al.. “Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.” Medicine (2026). PMID: 42536519 ↗
L1aCited in: Pathophysiology - [143]
Sang H, Liu X, Song J. “Visceral adipose tissue and acute pancreatitis: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42254660 ↗
L2aCited in: Pathophysiology - [144]
Ben Ismail I, Sghaier M, Zenaidi H et al.. “The Neutrophil-Creatinine Index as an Early Predictor of Severe Acute Pancreatitis.” The Journal of surgical research (2026). PMID: 42556197 ↗
L3bCited in: Pathophysiology - [145]
Pădureanu V, Florescu DN, Cazacu SM et al.. “Evaluation of oxidative stress in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42220490 ↗
L3bCited in: Pathophysiology - [146]
Huang A, Yuan Q, Chen J et al.. “Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.” NPJ digital medicine (2026). PMID: 42204286 ↗
L3bCited in: Pathophysiology - [147]
Gu H, Tang C, Shi Y et al.. “sEV-Enriched Serum Preparations From Healthy Individuals Protect Against Acute Pancreatitis-Induced Intestinal Barrier Dysfunction Through miR-579-3p/ANXA3-Mediated Inhibition of NLRP3 Inflammasome Pyroptosis.” Archivum immunologiae et therapiae experimentalis (2026). PMID: 42347491 ↗
L3bCited in: Pathophysiology - [148]
Chen X, Li Z, Mao T et al.. “Predictive value of sarcopenia-related clinical indices for early disease progression in acute pancreatitis: a multicenter retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42564036 ↗
L3bCited in: Pathophysiology - [149]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Pathophysiology - [150]
Wang Z, Liu Y, Li C. “Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.” Frontiers in nutrition (2026). PMID: 42459810 ↗
L3bCited in: Pathophysiology - [151]
Yu W, Yang P, Ding M et al.. “Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report.” Frontiers in medicine (2026). PMID: 42344497 ↗
L4Cited in: Pathophysiology - [152]
Ambli S, Gupta BK, Pandey AR et al.. “Comparison of the incidence of acute kidney injury in patients with acute pancreatitis managed with or without thoracic epidural analgesia: A prospective randomized controlled trial.” International journal of critical illness and injury science (2026). PMID: 42281814 ↗
L1bCited in: Pathophysiology - [153]
Turkmen B, Özel Yetkin M, Yenişekerci Kulak E et al.. “The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.” Digestive diseases and sciences (2026). PMID: 42570998 ↗
L3bCited in: Pathophysiology - [154]
Cohen BD, Eluri N, Levine S et al.. “Atrial fibrillation and cardiovascular comorbidity burden as predictors of in-hospital mortality in acute pancreatitis: A National Inpatient Sample analysis of 1.9 million hospitalizations.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42382912 ↗
L3bCited in: Pathophysiology - [155]
Mareninova OA, Chang AG, Hernandez Malpica S et al.. “Genetic and pharmacologic modulations elucidate NRF2 protective role in acute pancreatitis.” American journal of physiology. Gastrointestinal and liver physiology (2026). PMID: 42530545 ↗
L5Cited in: Pathophysiology - [156]
Pandanaboyana S, Knoph CS, Kuhlmann L et al.. “European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.” United European gastroenterology journal (2026). PMID: 42299777 ↗
L1cCited in: History and Physical Examination - [157]
Hammad N, Ramadan AM, Nazmy A et al.. “Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 41640110 ↗
L1aCited in: History and Physical Examination - [158]
Aguilar-Salinas CA, Alonso R, Berg G et al.. “A multi-society Delphi consensus statement on the diagnosis of familial chylomicronemia syndrome.” Archives of endocrinology and metabolism (2025). PMID: 41026863 ↗
L1cCited in: History and Physical Examination - [159]
Liu Y, Feng XY, Chen C et al.. “Nutritional recovery after minimally invasive pancreatic stone treatment: Body mass index dynamics and predictors in chronic pancreatitis cohorts.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 42108155 ↗
L2bCited in: History and Physical Examination - [160]
López FV, Kesavan P, Win LK et al.. “Hyperamylasaemia in paediatric inflammatory bowel disease: Aetiology, outcomes and genetic determinants.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42037072 ↗
L4Cited in: History and Physical Examination - [161]
Kuhlmann L, Davidsen L, Knoph CS et al.. “Trajectories of Pain Processing in Recurrent Acute and Chronic Pancreatitis: A Longitudinal Quantitative Sensory Testing Study.” European journal of pain (London, England) (2026). PMID: 41842672 ↗
L4Cited in: History and Physical Examination - [162]
Gao L, Zhang R, Xiao Y et al.. “High Serum Lipase Level is Associated With Increased Analgesic Use in Hospitalized Patients With Acute Pancreatitis.” Pain research & management (2026). PMID: 41808845 ↗
L3bCited in: History and Physical Examination - [163]
Tartaglia E, Bucci T, Rossi M et al.. “Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.” Cardiovascular diabetology (2025). PMID: 41257737 ↗
L3bCited in: History and Physical Examination - [164]
Gu RJ, Zhang YR. “Predictive utility of the triglyceride-glucose index and visceral adiposity-related indices for severe progression in hypertriglyceridemic pancreatitis.” Journal of clinical lipidology (2025). PMID: 41162245 ↗
L3bCited in: History and Physical Examination - [165]
Tarján D, Szalai EÁ, Erőss B et al.. “Safety and Effectiveness of Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography in Biliary Pancreatitis During Pregnancy: BORN Study.” United European gastroenterology journal (2025). PMID: 41045491 ↗
L4Cited in: History and Physical Examination - [166]
Zhou AL, Chiang JY, Chan KS et al.. “Decoding Alexander the Great's gastrointestinal cause of death using artificial wisdom: An artificial intelligence-human inquiry into a medical mystery.” World journal of gastroenterology (2025). PMID: 41479650 ↗
L3bCited in: History and Physical Examination - [167]
Barbar M, Kanaan D, AlZebin Z et al.. “Severe asparaginase-associated hypertriglyceridemia in pediatric acute lymphoblastic leukemia: a single-center experience.” Frontiers in oncology (2026). PMID: 42415868 ↗
L4Cited in: History and Physical Examination - [168]
Yu B, Li Y, Li N et al.. “Age-related vulnerability and clinical outcomes in acute pancreatitis: a stratified cohort study of 1,034 patients.” BMC gastroenterology (2026). PMID: 42304224 ↗
L3bCited in: History and Physical Examination - [169]
Jiang W, Peng J, Wu Q et al.. “Normal saline vs. lactated ringer's for fluid resuscitation in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42180723 ↗
L1aCited in: Supportive Care and Complication Management - [170]
Ding L, Wang Z, Wang Y et al.. “Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42420072 ↗
L1bCited in: Supportive Care and Complication Management - [171]
Elzayyat A, Altaie M, Shoaib MI et al.. “Total enteral vs. parenteral nutrition in severe acute pancreatitis: an updated systematic review and GRADE-assessed meta-analysis.” BMC nutrition (2026). PMID: 42087204 ↗
L1aCited in: Supportive Care and Complication Management - [172]
Wu Y, Gao Y, Fang Z et al.. “Time-dependent microbiology of peripancreatic drainage fluid in severe acute pancreatitis: a prospective real-world observational study using metagenomic sequencing and culture.” Frontiers in medicine (2026). PMID: 42328576 ↗
L2bCited in: Supportive Care and Complication Management - [173]
van den Berg FF, Pauw HS, Timmerhuis HC et al.. “Antibiotic-associated Enterococcus expansion in the gastrointestinal tract precedes infected necrosis in acute necrotizing pancreatitis.” Gut microbes (2026). PMID: 42141757 ↗
L2bCited in: Supportive Care and Complication Management - [174]
Ouyang S, Fan Y, Liu F et al.. “Automated CT Volumetry of Peripancreatic Collections for Risk Stratification in Acute Pancreatitis: A Multicenter Retrospective Study.” Academic radiology (2026). PMID: 42567794 ↗
L3bCited in: Supportive Care and Complication Management - [175]
Anandalwar SP, Clark J, Vesselinov R et al.. “Does the risk outweigh the benefit? Clot progression, recanalization & complications of anticoagulation therapy in acute pancreatitis with concomitant splanchnic vein thrombosis.” American journal of surgery (2026). PMID: 42398215 ↗
L3bCited in: Supportive Care and Complication Management - [176]
Long H, Lin J, Zheng R et al.. “Development of a Scoring System For Severe Acute Pancreatitis And Utility of US-guided Catheter Drainage in High-risk Patients.” Academic radiology (2026). PMID: 42161741 ↗
L3bCited in: Supportive Care and Complication Management - [177]
Zhang H, Chen D, Tian H et al.. “Perioperative nursing management in video-assisted retroperitoneal debridement for severe acute pancreatitis with infected peripancreatic necrosis: a retrospective single-center case series of 41 patients.” Frontiers in surgery (2026). PMID: 42369635 ↗
L4Cited in: Supportive Care and Complication Management - [178]
Desai V, Ancil S, Gupta R et al.. “Incidence and Determinants of Pancreatic Insufficiency After Acute Necrotizing Pancreatitis: A Prospective Study.” Digestive diseases and sciences (2026). PMID: 42154122 ↗
L2bCited in: Supportive Care and Complication Management - [179]
Zhang JX, Jin HS, Lu SS et al.. “Potential benefit of mirabilite external dressing combined with abdominal drainage in the early stage of severe acute pancreatitis.” BMC gastroenterology (2026). PMID: 42426625 ↗
L2bCited in: Supportive Care and Complication Management - [180]
Hayashi H, Kubo T, Hara T et al.. “Non-keratinizing immature squamous metaplasia in the pancreas mimicking malignancy: a diagnostic pitfall in cytology.” Journal of pathology and translational medicine (2026). PMID: 42452874 ↗
L3bCited in: Supportive Care and Complication Management - [181]
Lan L, Cheng G, He M et al.. “Fluid resuscitation in the early management of acute pancreatitis: a five-year retrospective observational study.” World journal of emergency medicine (2026). PMID: 42199765 ↗
L3bCited in: Supportive Care and Complication Management - [182]
Gokhe P, Karunakaran M, Gupta S et al.. “QUality of Life After Open Surgical Necrosectomy in Infected Pancreatic Necrosis (QUIP): Defining Targets for Long-Term Follow-up and Interventions.” Digestive diseases and sciences (2026). PMID: 42101798 ↗
L4Cited in: Supportive Care and Complication Management - [183]
Li M, Fu Y, Chen Y et al.. “Case Report: Early documented infected pancreatic necrosis due to carbapenem-resistant Acinetobacter baumannii and concurrent Enterococcus faecium bacteremia: a salvage regimen with sulbactam-durlobactam and tigecycline.” Frontiers in medicine (2026). PMID: 42440864 ↗
L4Cited in: Supportive Care and Complication Management - [184]
Jacq E, Maire F, Cucherousset J et al.. “From Cutaneous Necrosis to Septic Shock: An ICU Case of Pancreatico portal Fistula Complicating Necrotizing Acute Pancreatitis.” Critical care explorations (2026). PMID: 42390290 ↗
L4Cited in: Supportive Care and Complication Management - [185]
Wei H, Sun DY, Wang XY et al.. “Clinical application of self-made ENBD drainage tube in the treatment of pancreatic pseudocyst: a case report.” Frontiers in medicine (2026). PMID: 42221067 ↗
L4Cited in: Supportive Care and Complication Management - [186]
Tekdemir H, Sözeri A, Çifçi BE. “CT-derived visceral adiposity and paraspinal muscle depletion associated with severe acute pancreatitis according to the Revised Atlanta Classification.” Abdominal radiology (New York) (2026). PMID: 42720761 ↗
L3bCited in: Definition, Synonyms, and Classification - [187]
Ojala T, Bonsdorff A, Parviainen H et al.. “Comparing and validation of definitions of postoperative acute pancreatitis after pancreatoduodenectomy and proposal for Atlanta-Helsinki grading system.” Surgery (2026). PMID: 42575742 ↗
L3bCited in: Definition, Synonyms, and Classification - [188]
Chen X, Zhou L, Huang Y et al.. “Hemoperfusion with Hemodiafiltration Versus Standard Medical Therapy for Severe Acute Pancreatitis: A Retrospective Study.” Digestive diseases and sciences (2026). PMID: 42702672 ↗
L1bCited in: Pathophysiology - [189]
Yao Y, Yuan B, Wang K et al.. “An explainable machine learning framework integrating clinical and lipidomic signatures for early severity stratification of hypertriglyceridemic pancreatitis.” Frontiers in medicine (2026). PMID: 42638867 ↗
L2bCited in: Pathophysiology - [190]
Farrell PR, Lee B, Ahmed F et al.. “TRANCE is a unique marker of chronic pancreatitis in children.” JCI insight (2026). PMID: 42635043 ↗
L2bCited in: Pathophysiology - [191]
Ye HW, Liu F, Gu DJ et al.. “Impact of acute cholangitis severity on the safety of laparoscopic common bile duct exploration with primary closure: a stratified retrospective study.” Surgical endoscopy (2026). PMID: 42680926 ↗
L3bCited in: Pathophysiology - [192]
Vazzana GF, Romano A, Romano C. “Idiopathic Acute Pancreatitis in Paediatric Inflammatory Bowel Disease: Clinical Features and Outcomes in a Retrospective Single-Centre Study.” Journal of paediatrics and child health (2026). PMID: 42625467 ↗
L4Cited in: Pathophysiology - [193]
Kosidło JW, Dorf J, Kamińska J et al.. “Unveiling the multidimensional cytokine landscape in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42643960 ↗
L3bCited in: Pathophysiology - [194]
Obeidat A, Sallam A, Chang C. “Clinical and in-hospital outcomes of alcohol-related pancreatitis in the setting of concomitant alcohol-related hepatitis: A retrospective cohort study.” The American journal of the medical sciences (2026). PMID: 42580663 ↗
L3bCited in: Pathophysiology - [195]
Chen C, Zhao Y, Lin X et al.. “Case Report: A rare case of concurrent diabetic ketoacidosis and severe acute pancreatitis, followed by Guillain-Barré syndrome and Wernicke's encephalopathy.” Frontiers in endocrinology (2026). PMID: 42718484 ↗
L4Cited in: Pathophysiology - [196]
Mititelu A, Grama A, Bența G et al.. “Acute and Recurrent Pancreatitis in Children: Insights into Etiology and Clinical Course from a Retrospective Single-Center Study.” Children (Basel, Switzerland) (2026). PMID: 42650422 ↗
L3bCited in: History and Physical Examination - [197]
Bhattarai S, Baral S, Bhowmick M et al.. “Short-Term Changes in Body Composition and the Development of Sarcopenia Following Acute Pancreatitis: An Observational Study.” Digestive diseases and sciences (2026). PMID: 42223541 ↗
L3bCited in: History and Physical Examination - [198]
Agaoglu Z, Toptas GR, Serbetci H et al.. “Evaluation of Maternal and Fetal Outcomes in Pregnant Women with Acute Pancreatitis: A Five-Year Retrospective Study from a Tertiary Center.” Digestive diseases and sciences (2026). PMID: 42154121 ↗
L3bCited in: History and Physical Examination - [199]
Roberts KM, Thongkhao-On S, Culp S et al.. “Dietary Patterns Following an Episode of Acute Pancreatitis: A Post Hoc Analysis From the PAPPEI Multicenter, Prospective Study.” Pancreas (2026). PMID: 42047302 ↗
L3bCited in: History and Physical Examination - [200]
Chen SC, Liu KW, Huang YN et al.. “Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.” American journal of therapeutics (2026). PMID: 41992281 ↗
L3bCited in: History and Physical Examination - [201]
Chleirigh NN, O'Broin ER, Shet S et al.. “10 year cumulative diagnostic radiation exposure after acute pancreatitis: a retrospective comparison of acute interstitial oedematous and necrotising pancreatitis.” BMC gastroenterology (2026). PMID: 41888675 ↗
L4Cited in: History and Physical Examination - [202]
Calabrese EC, Shehata D, Slater BJ et al.. “SAGES clinical practice guidelines for the management of symptomatic walled-off pancreatic necrosis.” Surgical endoscopy (2026). PMID: 42675307 ↗
L1cCited in: Supportive Care and Complication Management - [203]
Fang Y, Chen X, Cai L et al.. “Comparative efficacy and safety of Xuesaitong injection as adjuvant therapy for acute pancreatitis: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42591735 ↗
L1aCited in: Supportive Care and Complication Management - [204]
Chen X, Su L, Zhang D et al.. “Association between peak D-dimer levels within 24 hours of admission and the risk of infected pancreatic necrosis in hyperlipidemic acute pancreatitis: a retrospective analysis.” Frontiers in medicine (2026). PMID: 42712372 ↗
L3bCited in: Supportive Care and Complication Management - [205]
Zuo Q, Cui M, Li J et al.. “Robot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study.” Journal of robotic surgery (2026). PMID: 42671732 ↗
L3bCited in: Supportive Care and Complication Management - [206]
Grover AS, Reiss DE, Templeton K et al.. “Endoscopic ultrasound-guided drainage of pancreatic fluid collections is safe to perform in children: A comparison of two endoscopic approaches.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42626823 ↗
L4Cited in: Supportive Care and Complication Management